Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CELive EventsScientific InterchangesState of the Science SummitNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Watch
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Gilles A. Salles, MD, PhD

Advertisement

Articles by Gilles A. Salles, MD, PhD

Dr. Salles on Improving Immune Respone in Follicular Lymphoma

ByGilles A. Salles, MD, PhD
February 14th 2017

Gilles A. Salles, MD, PhD, Centre Hospitalier Lyon-Sud, discusses improving immune response in follicular lymphoma.

Advertisement

Latest Updated Articles

  • Dr. Salles on Improving Immune Respone in Follicular Lymphoma
    Dr. Salles on Improving Immune Respone in Follicular Lymphoma

    February 14th 2017



Advertisement
Advertisement

Trending on OncLive

1

A New Era in Pancreatic Cancer Treatment: Daraxonrasib Shakes Up the Landscape

2

INCB161734 Combination Data Shape DAWN-303’s All-Comers Design in Frontline KRAS G12D-Mutated PDAC

3

Krascendo 1 Survival Data Position Divarasib to Reset Second-Line Standards and Fuel First-Line Combinations in KRAS G12C–Mutated NSCLC

4

Fox Chase Cancer Center Researchers Identify Potential New Target for Pancreatic Cancer

5

OncLive Weekly News Quiz (10/30/2026): Did You Miss Crucial Prostate, HNSCC, and Hematologic Cancer Updates?

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us